恒瑞医药：自主研发1类生物制品SHR1179注射液获批临床

财中社09-07 17:03

9月7日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司收到国家药品监督管理局核准签发的关于SHR-1179注射液的《药物临床试验批准通知书》，将于近期开展临床试验。　　该药物为公司自主研发的治疗用1类生物制品，拟用于体重管理适应症，国内外暂无相同靶点药物获批上市。截至目前，SHR-1179注射液相关项目累计研发投入约为2420万元（未经审计）。　　2026年中期，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2665318079?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-07 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665318079","market":"hk","top_or_hot":-1,"title":"恒瑞医药：自主研发1类生物制品SHR1179注射液获批临床","media":"财中社","content":"<div>\n<p>9月7日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司收到国家药品监督管理局核准签发的关于SHR-1179注射液的《药物临床试验批准通知书》，将于近期开展临床试验。　　该药物为公司自主研发的治疗用1类生物制品，拟用于体重管理适应症，国内外暂无相同靶点药物获批上市。截至目前，SHR-1179注射液相关项目累计研发投入约为2420万元（未经审计）。　　2026年中期，...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609073866736252.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药：自主研发1类生物制品SHR1179注射液获批临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药：自主研发1类生物制品SHR1179注射液获批临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-07 17:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202609073866736252.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月7日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司收到国家药品监督管理局核准签发的关于SHR-1179注射液的《药物临床试验批准通知书》，将于近期开展临床试验。　　该药物为公司自主研发的治疗用1类生物制品，拟用于体重管理适应症，国内外暂无相同靶点药物获批上市。截至目前，SHR-1179注射液相关项目累计研发投入约为2420万元（未经审计）。　　2026年中期，...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609073866736252.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0405327494.USD","symbol_name":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202609073866736252.html","article_id":"2665318079","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866736252.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2665318079","pubTimestamp":1788771780,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"9月7日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司收到国家药品监督管理局核准签发的关于SHR-1179注射液的《药物临床试验批准通知书》，将于近期开展临床试验。该药物为公司自主研发的治疗用1类生物制品，拟用于体重管理适应症，国内外暂无相同靶点药物获批上市。截至目前，SHR-1179注射液相关项目累计研发投入约为2420万元（未经审计）。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0196":"行业龙头","01276":"恒瑞医药","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0239":"医药制造","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0359201612.USD":"贝莱德中国基金A2","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0183":"MSCI概念","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0188":"融资融券","BK0012":"证金概念","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1997245177.USD":"安联神洲A股基金","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK0028":"国家队","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1191":"制药","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0060":"抗癌","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A"},"translate_title":"Hengrui Medicine: Independently developed Class 1 biological product SHR1179 injection approved for clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5},"content_text":"9月7日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司收到国家药品监督管理局核准签发的关于SHR-1179注射液的《药物临床试验批准通知书》，将于近期开展临床试验。　　该药物为公司自主研发的治疗用1类生物制品，拟用于体重管理适应症，国内外暂无相同靶点药物获批上市。截至目前，SHR-1179注射液相关项目累计研发投入约为2420万元（未经审计）。　　2026年中期，恒瑞医药实现收入154.56亿元，归母净利润44.65亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2665318079","isCrawlerRequest":true}